Merck commits $1.85B to Pandion in bid to boost immunology pipeline February 25, 2021 Auto Bot autoimmune diseases, BioPharma, biopharma nl, Kenilworth, Merck, New Jersey, Pharma 0 Merck’s top immunology drugs face biosimiliar competition. The $1.85 billion acquisition of Pandion Therapeutics gives the pharma giant an opportunity to build up its immunology pipeline with a new approach to treating autoimmune disorders.